Greyling A, De Witt C, Oosthuizen W, Jerling J C
School of Physiology, Nutrition and Consumer Sciences, North-West University (Potchefstroom Campus), South Africa.
Br J Nutr. 2006 May;95(5):968-75. doi: 10.1079/bjn20061715.
Policosanol is a mixture of higher aliphatic primary alcohols that is extracted from purified sugar cane wax or a variety of other plant sources, and has been shown to have beneficial effects on serum lipid concentrations. The objective of this study was to investigate the effects of a policosanol supplement (Octa-60) on lipid profiles of hypercholesterolaemic and heterozygous familial hypercholesterolaemic subjects. Nineteen hypercholesterolaemic and familial hypercholesterolaemic subjects completed this randomised, placebo-controlled, double-blind study. The subjects received either a daily dose of 20 mg policosanol or placebo for 12 weeks. After a wash-out period of 4 weeks, the interventions were crossed over. Lipid levels were measured at baseline and at the end of each intervention period. No significant differences in total cholesterol and LDL-cholesterol from baseline to end or between policosanol and placebo were seen in the hypercholesterolaemic or familial hypercholesterolaemic groups. There were small reductions in total cholesterol and LDL-cholesterol from baseline to end in the hypercholesterolaemic group, but these changes did not differ significantly from the changes with the placebo, indicating that the observed decrease in cholesterol in the policosanol group was not due to the specific effect of policosanol treatment. The differences in response may be ascribed to the differences in composition of the higher aliphatic primary alcohols in the previously used products, compared with the local policosanol supplement. An intake of 20 mg/d policosanol for 12 weeks had no significant effect on serum lipid levels in hypercholesterolaemic and heterozygous familial hypercholesterolaemic patients when compared with placebo intake.
聚多卡醇是一种从纯化甘蔗蜡或多种其他植物来源中提取的高级脂肪族伯醇混合物，已被证明对血清脂质浓度有有益影响。本研究的目的是调查聚多卡醇补充剂（Octa - 60）对高胆固醇血症和杂合子家族性高胆固醇血症患者血脂谱的影响。19名高胆固醇血症和家族性高胆固醇血症患者完成了这项随机、安慰剂对照、双盲研究。受试者接受每日20毫克聚多卡醇或安慰剂治疗12周。经过4周的洗脱期后，干预措施交叉进行。在基线和每个干预期结束时测量血脂水平。在高胆固醇血症或家族性高胆固醇血症组中，从基线到结束时以及聚多卡醇和安慰剂之间的总胆固醇和低密度脂蛋白胆固醇均无显著差异。高胆固醇血症组从基线到结束时总胆固醇和低密度脂蛋白胆固醇有小幅降低，但这些变化与安慰剂的变化无显著差异，表明聚多卡醇组中观察到的胆固醇降低并非由于聚多卡醇治疗的特定作用。与当地聚多卡醇补充剂相比，先前使用产品中高级脂肪族伯醇组成的差异可能导致了反应差异。与安慰剂摄入相比，每日摄入20毫克聚多卡醇持续12周对高胆固醇血症和杂合子家族性高胆固醇血症患者的血清脂质水平无显著影响。
